Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (75)

2024

  1. Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects

    Diabetes Therapy, Vol. 15, Núm. 7, pp. 1501-1512

2022

  1. Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials

    Diabetes, Obesity and Metabolism, Vol. 24, Núm. 4, pp. 631-640

  2. The Effect of Teriparatide Treatment on the Risk of Fragility Fractures in Postmenopausal Women with Osteoporosis: Results from the Asian and Latin America Fracture Observational Study (ALAFOS)

    Calcified Tissue International, Vol. 110, Núm. 1, pp. 74-86

2021

  1. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

    The Lancet, Vol. 398, Núm. 10300, pp. 583-598

  2. Teriparatide

    Osteoporotic Fracture and Systemic Skeletal Disorders: Mechanism, Assessment, and Treatment (Springer Nature), pp. 339-359

  3. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

    The Lancet, Vol. 398, Núm. 10313, pp. 1811-1824

  4. Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained

    Journal of Bone and Mineral Research, Vol. 36, Núm. 2, pp. 236-243

2020

  1. Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical Trial

    Calcified Tissue International, Vol. 106, Núm. 6, pp. 646-654

  2. Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c

    Journal of Diabetes and its Complications, Vol. 34, Núm. 7

  3. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials

    The Lancet Diabetes and Endocrinology, Vol. 8, Núm. 8, pp. 672-682

2019

  1. Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials

    Journal of Bone and Mineral Research, Vol. 34, Núm. 4, pp. 632-642

  2. Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis

    Bone, Vol. 120, pp. 1-8

  3. Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies

    Calcified Tissue International, Vol. 104, Núm. 2, pp. 193-200

  4. Reply to: Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials

    Journal of Bone and Mineral Research

  5. Study description and baseline characteristics of the population enrolled in a multinational, observational study of teriparatide in postmenopausal women with osteoporosis: the Asia and Latin America Fracture Observational Study (ALAFOS)

    Current Medical Research and Opinion, Vol. 35, Núm. 6, pp. 1041-1049

2018

  1. Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS)

    Calcified Tissue International, Vol. 103, Núm. 4, pp. 359-371

  2. Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies

    Bone, Vol. 116, pp. 58-66

  3. Teriparatide Treatment Increases Mineral Content and Volume in Cortical and Trabecular Bone of Iliac Crest: A Comparison of Infrared Imaging With X-Ray–Based Bone Assessment Techniques

    Journal of Bone and Mineral Research, Vol. 33, Núm. 12, pp. 2230-2235

2017

  1. Effect of Teriparatide or Risedronate in Elderly Patients With a Recent Pertrochanteric Hip Fracture: Final Results of a 78-Week Randomized Clinical Trial

    Journal of Bone and Mineral Research, Vol. 32, Núm. 5, pp. 1040-1051

  2. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)

    Diabetes, Obesity and Metabolism, Vol. 19, Núm. 7, pp. 1024-1031